Program Signaling and Experimental Therapeutics

项目总结(见说明)： 癌症信号转导与实验治疗学 癌症信号和实验治疗(CSET)计划的研究重点是细胞信号通路及其如何影响癌症进展和治疗。该计划成员的总体目标是阐明与肿瘤生物学相关的基本信号机制，并将这些知识应用于发现和开发新的治疗方法。在该计划的研究中有两个主要的重叠主题：第一个主题是癌症信号，由三个相互关联的研究领域组成：GTP酶和激酶、激素信号和细胞黏附信号。第二个主题是实验治疗学，由三个相互关联的研究领域组成：药物输送和RNA干扰、小分子和临床试验。在过去的资助期间，癌症信号和实验治疗计划的主要成就包括确定乳腺癌雌激素受体信号的新治疗靶点，新的异戊二烯类抗癌化合物进入临床前验证研究，以及开发基于RNA适体的系统递送治疗前列腺癌的RNA干扰。在该计划的成员之间以及与其他癌症中心计划的成员之间，过去和现在都有许多富有成效的合作。例如，在 项目共同负责人Hohl博士和Wiemer博士合作开发具有抗癌活性的新型异戊二烯化合物，并将这些化合物用于临床试验，项目负责人Henry博士分别与癌症遗传学和计算生物学以及癌症流行病学项目的负责人Quelle博士和Lynch博士分享了NCI和NIH的拨款，并于最近与Dr. Ballas是癌症免疫学和免疫治疗项目的负责人。该计划由来自7个基础科学、8个临床科室和3个学院的45名成员组成。经过同行评审，该项目的研究资金总额为980万美元，其中350万美元来自NCI。项目成员发表了339篇与癌症相关的文章 上一次资助期间的论文。在这些出版物中，8%是方案内出版物，27%是方案间出版物，2%是方案内和方案间出版物，总共有37%是协作性出版物。

PROJECT SUMMARY (See instructions): Cancer Signaling and Experimental Therapeutics Research in the Cancer Signaling and Experimental Therapeutics (CSET) Program focuses cell signaling pathways and how they impact cancer progression and therapy. The overall goal of the members of this program is to elucidate basic signaling mechanisms relevant to tumor biology and apply this knowledge to the discovery and development of new therapeutic approaches. There are two major overiapping themes within the Program's research: The first theme is Cancer Signaling and is comprised of three interrelated research areas; GTPases and kinases, hormonal signaling and cell adhesion signaling. The second theme is Experimental Therapeutics and is comprised of three interrelated research areas; drug delivery and RNA interference, small molecules and clinical trials. Major accomplishments of the Cancer Signaling and Experimental Therapeutics Program over the past funding period include identification of a new therapeutic target in estrogen receptor signaling in breast cancer, advancement of novel isoprenoid anti-cancer compounds into pre-clinical validation studies, and development of RNA-aptamer-based systemic delivery of RNA-interference in prostate cancer. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. For example, within the program Co-leader Dr. Hohl and Dr. Wiemer have collaborated to develop novel isoprenoid compounds with anti-cancer activity and advance these toward clinical trials and Program Leader Dr. Henry shares separate NCI and NIH grant funding with Drs. Quelle and Lynch, Leaders of the Cancer Genetics and Computational Biology and Cancer Epidemiology programs, respectively and has published recently with Dr. Ballas Leader of the Cancer Immunology and Immunotherapy program. The program consists of 45 members from 7 basic science and 8 clinical departments and 3 Colleges. Peer-reviewed, research funding for this program totals $9.8 million with $3.5 million coming from the NCI. Program members published 339 cancer related papers over the prior funding period. Of these publications, 8% were intraprogrammatic, 27% were interprogrammatic and 2% were both intra and interprogrammatic, for a total of 37% collaborative publications.